Showing results (21-30 of 394) with videos related to
Sort By:
Pageof 40
Therapeutic Advances in Hematology|April 5, 2013
Novel targeted treatment strategies for refractory chronic lymphocytic leukaemiaAndrea Schnaiter, Stephan StilgenbauerHematology/Oncology Clinics of North America|April 9, 2013
17p deletion in chronic lymphocytic leukemia: risk stratification and therapeutic approachAndrea Schnaiter, Stephan StilgenbauerExpert Opinion on Pharmacotherapy|March 13, 2020
Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphomaDirk L Kienle, Stephan StilgenbauerLeukemia & Lymphoma|February 3, 2015
How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?Constantine S Tam, Stephan StilgenbauerClinics in Laboratory Medicine|November 29, 2011
Genetics of chronic lymphocytic leukemiaAndrea Schnaiter, Daniel Mertens, Stephan StilgenbauerOncology Research and Treatment|February 19, 2016
Genomic Features: Impact on Pathogenesis and Treatment of Chronic Lymphocytic LeukemiaEugen Tausch, Daniel Mertens, Stephan StilgenbauerBest Practice & Research. Clinical Haematology|August 21, 2007
Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemiaThorsten Zenz, Hartmut Döhner, Stephan StilgenbauerOncology Research and Treatment|April 17, 2015
Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibodyValentin Goede, Christian Klein, Stephan StilgenbauerHematology. American Society of Hematology. Education Program|December 7, 2024
Risk-stratification in frontline CLL therapy: standard of careEugen Tausch, Christof Schneider, Stephan StilgenbauerF1000Prime Reports|August 29, 2014
Advances in treating chronic lymphocytic leukemiaEugen Tausch, Daniel Mertens, Stephan StilgenbauerPageof 40